The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the ...
Table 2: TAK-935 Competitors; Abbreviations: DS, Dravet Syndrome; LS, Lennox-Gastaut Syndrome; TSC, Tuberous Sclerosis Complex. (Created by the Author from multiple resources) There is significant ...
After flunking two phase 3 trials, Relmada Therapeutics has turned over the open-label card for its depression med, providing the first bit of optimism in months, if not years, for the central-nervous ...
On Saturday April 5, Anavex announced data from their open-label extension trial, ATTENTION-AD, for early Alzheimer's Disease presented at the AD/PDTM 2025 Conference. ATTENTION-AD is a follow-on ...
TipRanks on MSN
MicroPort NeuroTech steps up competition in brain vascular devices with new embolic agent trial
MicroPort NeuroTech Limited ($HK:2172) announced an update on their ongoing clinical study. Study Overview The clinical study “a Prospective, ...
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company’s ongoing Phase 3 ARGUS trial investigating EPX-100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback